Results 61 to 70 of about 10,710,575 (236)

Mammographic density and molecular subtypes of breast cancer. [PDF]

open access: yes, 2012
BACKGROUND: Gene expression profiling has led to a subclassification of breast cancers independent of established clinical parameters, such as the Sorlie-Perou subtypes.
Bergh, J   +21 more
core   +1 more source

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 [PDF]

open access: yes, 2011
The associations of the 12 SNPs with risk for BRCA1 and BRCA2 carriers differ by ER-positive or ER-negative breast cancer status. The apparent differences in SNP associations between BRCA1 and BRCA2 carriers, and non-carriers, may be explicable by ...
Donaldson, A.   +999 more
core   +5 more sources

Breast cancer

open access: yesJAAPA
Breast cancer kills hundreds of thousands of people every year. Rapid progress over the past two decades has increased our understanding of the genetic and environmental risk factors for disease. It has also shed light on drivers of tumor progression and the molecular landscape underpinning tumor heterogeneity, as well as the role of the ...
Visvader, Jane E.   +2 more
openaire   +5 more sources

Breast cancer: A review of risk factors and diagnosis

open access: yesMedicine
Breast cancer remains a complex and prevalent health concern affecting millions of individuals worldwide. This review paper presents a comprehensive analysis of the multifaceted landscape of breast cancer, elucidating the diverse spectrum of risk factors
E. Obeagu, G. U. Obeagu
semanticscholar   +1 more source

RETRACTED ARTICLE: Cyclin D3 predicts disease-free survival in breast cancer

open access: yesCancer Cell International, 2015
Background Cyclin D3, which induces progression through the G1 phase of the cell cycle, is a regulator of Cyclin-dependent kinases 4 and 6. Previous studies revealed that abnormal expression of Cyclin D3 was found in many different cancers.
Yayun Chi   +5 more
doaj   +1 more source

Guideline for the Management Pathway and Quality Control of Breast Cancer Prevention and Treatment in China's Counties

open access: yesCancer Innovation
Breast cancer is one of the most common malignant tumors among women in China, with approximately 306,000 new cases reported in 2016. Notably, around 33% (100,400) of these cases occurred in rural areas.
Breast Cancer Expert Committee of National Cancer Quality Control Center   +1 more
doaj   +1 more source

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies

open access: yesBreast Cancer Research
Purpose Endocrine therapy (ET) with or without abemaciclib/ribociclib is the current standard for intermediate- and high-risk hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients. The NATALEE trial showed that adding 3 years of
Sonia Servitja   +20 more
doaj   +1 more source

Multicenter prospective study of dedicated breast positron emission tomography (dbPET) for breast cancer: examination in preoperative patients

open access: yesBMC Medical Imaging
Background Dedicated breast positron emission tomography (dbPET) was developed to detect breast cancers smaller than those detectable using whole-body PET (wbPET).
Youko Satou   +3 more
doaj   +1 more source

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer

open access: yesNature Communications, 2018
Triple negative breast cancers harbor multiple copy number aberrations driving gene expression changes thought to underpin their malignant phenotypes. Here the authors integrate these features, finding and functionally validating 37 gene addictions among
Nirmesh Patel   +20 more
doaj   +1 more source

Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

open access: yesBiomarker Research
Background Anthracycline-based chemotherapy, while foundational in breast cancer treatment, confers substantial cardiotoxicity. Identifying biomarkers to guide anthracycline exemption without compromising efficacy has remained an unresolved clinical ...
Zehao Wang   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy